Epidermal growth factor receptor mutational status and brain metastases in non–small-cell lung cancer

Journal of Global Oncology

Volumn 3, Issue 3, 2017, Pages 208-217

  Bhatt, Vijaya Raj ^a   D’Souza, Sanyo P ^c   Smith, Lynette M ^a   Cushman Vokoun, Allison M ^a   Noronha, Vanita ^c   Verma, Vivek ^a   Joshi, Amit ^c   Chougule, Anuradha ^c   Jambhekar, Nirmala ^c   Kessinger, Anne ^a   Marr, Alissa ^a   Patil, Vijay ^c   Banavali, Sripad D ^c   Ganti, Apar Kishor ^a,b   Prabhash, Kumar ^c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^c TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85096801420     PISSN: None     EISSN: 23789506     Source Type: Journal    
DOI: 10.1200/JGO.2016.003392     Document Type: Article

References (37)

1. Zimmermann S, Dziadziuszko R, Peters S: Indications and limitations of chemotherapy and targeted agents in nonsmall cell lung cancer brain metastases. Cancer Treat Rev 40:716-722, 2014
2. Langer CJ: Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: Is afatinib better or simply newer? J Clin Oncol 31:3303-3306, 2013
3. Small AC, Tsao C-K, Moshier EL, et al: Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. Cancer 118:5947-5954, 2012
4. Lindeman NI, Cagle PT, Beasley MB, et al: Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8:823-859, 2013
5. Seshacharyulu P, Ponnusamy MP, Haridas D, et al: Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16:15-31, 2012
6. Ganti AK: Epidermal growth factor receptor signaling in nonsmall cell lung cancer. Cancer Invest 28:515-525, 2010
7. Rosell R, Moran T, Queralt C, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-967, 2009
8. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
9. Welsh JW, Komaki R, Amini A, et al: Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 31:895-902, 2013
10. Bhatt VR, Kedia S, Kessinger A, et al: Brain metastasis in patients with non-small-cell lung cancer and epidermal growth factor receptor mutations. J Clin Oncol 31:3162-3164, 2013
11. Chougule A, Prabhash K, Noronha V, et al: Frequency of EGFR mutations in 907 lung adenocarcinoma patients of Indian ethnicity. PLoS One 8:e76164, 2013
12. Shin DY, Na II, Kim CH, et al: EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol 9: 195-199, 2014
13. Stanic K, Zwitter M, Hitij NT, et al: Brain metastases in lung adenocarcinoma: Impact of EGFR mutation status on incidence and survival. Radiol Oncol 48:173-183, 2014
14. Sekine A, Kato T, Hagiwara E, et al: Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: Distinguishing influence of exon 19 deletion on radiographic features. Lung Cancer 77:64-69, 2012
15. Gazdar AF, Minna JD: Deregulated EGFR signaling during lung cancer progression: Mutations, amplicons, and autocrine loops. Cancer Prev Res (Phila) 1:156-160, 2008
16. Yatabe Y, Matsuo K, Mitsudomi T: Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 29:2972-2977, 2011
17. Yatabe Y, Takahashi T, Mitsudomi T: Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res 68:2106-2111, 2008
18. Sun M, Behrens C, Feng L, et al: HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res 15:4829-4837, 2009
19. Benedettini E, Sholl LM, Peyton M, et al: Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 177:415-423, 2010
20. Buonato JM, Lazzara MJ: ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition. Cancer Res 74:309-319, 2014
21. Park KS, Raffeld M, Moon YW, et al: CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. J Clin Invest 124:3003-3015, 2014
22. Regine WF, Scott C, Murray K, et al: Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs. accelerated-hyperfractionated radiotherapy: An analysis from Radiation Therapy Oncology Group Study 91-04. Int J Radiat Oncol Biol Phys 51:711-717, 2001
23. Xie SS, Li M, Zhou CC, et al: Prophylactic cranial irradiation may impose a detrimental effect on overall survival of patients with nonsmall cell lung cancer: A systematic review and meta-analysis. PLoS One 9:e103431, 2014
24. Lester JF, MacBeth FR, Coles B: Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small-cell lung cancer: A Cochrane Review. Int J Radiat Oncol Biol Phys 63:690-694, 2005
25. Mujoomdar A, Austin JH, Malhotra R, et al: Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: Primary tumor size, cell type, and lymph node metastases. Radiology 242:882-888, 2007
26. Na II, Lee TH, Choe DH, et al: A diagnostic model to detect silent brain metastases in patients with non-small cell lung cancer. Eur J Cancer 44:2411-2417, 2008
27. Wang SY, Ye X, Ou W, et al: Risk of cerebral metastases for postoperative locally advanced non-small-cell lung cancer. Lung Cancer 64:238-243, 2009
28. Li N, Zeng Z-F, Wang S-Y, et al: Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA-N2 non-small-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy. Ann Oncol 26:504-509, 2015
29. Wu M, Zhao J, Song SW, et al: EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer 67:343-347, 2010
30. Eberhard DA, Johnson BE, Amler LC, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909, 2005
31. Li H, Zhang X, Cao J, et al: Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer. Tumour Biol 36:9251-9258, 2015
32. Berry MF, Jeffrey Yang CF, Hartwig MG, et al: Impact of pulmonary function measurements on long-term survival after lobectomy for stage I non-small cell lung cancer. Ann Thorac Surg 100:271-276, 2015
33. Yang JC, Wu YL, Schuler M, et al: Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16:141-151, 2015
34. Sheng M, Wang F, Zhao Y, et al: Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: A meta-analysis. Eur J Clin Pharmacol 72:1-11, 2016
35. Mitsudomi T: Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations. Transl Lung Cancer Res 3:205-211, 2014
36. Doval D, Prabhash K, Patil S, et al: Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. Onco Targets Ther 8:117-123, 2015
37. Pham D, Kris MG, Riely GJ, et al: Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 24:1700-1704, 2006